125 related articles for article (PubMed ID: 17668540)
1. An open-label study to evaluate the transition of patients with chronic plaque psoriasis from cyclosporine to alefacept.
Magliocco MA; Lozano AM; Van Saders C; Schuler KW; Gottlieb AB
J Drugs Dermatol; 2007 Apr; 6(4):424-7. PubMed ID: 17668540
[TBL] [Abstract][Full Text] [Related]
2. A multicenter, open-label study of repeat courses of intramuscular alefacept in combination with other psoriasis therapies in patients with chronic plaque psoriasis.
Krueger GG; Gottlieb AB; Sterry W; Korman N; Van De Kerkhof P
J Dermatolog Treat; 2008; 19(3):146-55. PubMed ID: 18569270
[TBL] [Abstract][Full Text] [Related]
3. A randomized controlled study of combination therapy with alefacept and narrow band UVB phototherapy (UVB) for moderate to severe psoriasis: efficacy, onset, and duration of response.
Lui H; Gulliver W; Tan J; Hong CH; Hull P; Shear NH; Paradiso-Hardy F; Bissonette R
J Drugs Dermatol; 2012 Aug; 11(8):929-37. PubMed ID: 22859237
[TBL] [Abstract][Full Text] [Related]
4. Alefacept: its safety profile, off-label uses, and potential as part of combination therapies for psoriasis.
Scheinfeld N
J Dermatolog Treat; 2007; 18(4):197-208. PubMed ID: 17671880
[TBL] [Abstract][Full Text] [Related]
5. Clinical effectiveness and safety experience with alefacept in the treatment of patients with moderate-to-severe chronic plaque psoriasis in Taiwan: results of an open-label, single-arm, multicentre pilot study.
Huang PH; Liao YH; Wei CC; Tseng YH; Ho JC; Tsai TF
J Eur Acad Dermatol Venereol; 2008 Aug; 22(8):923-30. PubMed ID: 18312328
[TBL] [Abstract][Full Text] [Related]
6. Treatment of moderate-to-severe psoriasis with alefacept for up to one year: a case series.
Shah A; O'Neill J; Feldman SR
J Drugs Dermatol; 2010 Dec; 9(12):1491-4. PubMed ID: 21120256
[TBL] [Abstract][Full Text] [Related]
7. An open-label study of alefacept plus ultraviolet B light as combination therapy for chronic plaque psoriasis.
Ortonne JP; Khemis A; Koo JY; Choi J
J Eur Acad Dermatol Venereol; 2005 Sep; 19(5):556-63. PubMed ID: 16164708
[TBL] [Abstract][Full Text] [Related]
8. Alefacept in combination with ultraviolet B phototherapy for the treatment of chronic plaque psoriasis: results from an open-label, multicenter study.
Koo JY; Bagel J; Sweetser MT; Ticho BS
J Drugs Dermatol; 2006; 5(7):623-8. PubMed ID: 16865867
[TBL] [Abstract][Full Text] [Related]
9. An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy.
Goffe B; Papp K; Gratton D; Krueger GG; Darif M; Lee S; Bozic C; Sweetser MT; Ticho B
Clin Ther; 2005 Dec; 27(12):1912-21. PubMed ID: 16507377
[TBL] [Abstract][Full Text] [Related]
10. Changes in circulating lymphocyte subpopulations following administration of the leucocyte function-associated antigen-3 (LFA-3)/IgG1 fusion protein alefacept.
Larsen R; Ryder LP; Svejgaard A; Gniadecki R
Clin Exp Immunol; 2007 Jul; 149(1):23-30. PubMed ID: 17403057
[TBL] [Abstract][Full Text] [Related]
11. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes.
Ellis CN; Krueger GG;
N Engl J Med; 2001 Jul; 345(4):248-55. PubMed ID: 11474662
[TBL] [Abstract][Full Text] [Related]
12. Treatment of psoriasis with alefacept: correlation of clinical improvement with reductions of memory T-cell counts.
Gordon KB; Vaishnaw AK; O'Gorman J; Haney J; Menter A;
Arch Dermatol; 2003 Dec; 139(12):1563-70. PubMed ID: 14676071
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of alefacept in elderly patients and other special populations.
Gottlieb AB; Boehncke WH; Darif M
J Drugs Dermatol; 2005; 4(6):718-24. PubMed ID: 16302557
[TBL] [Abstract][Full Text] [Related]
14. Alefacept revisited: Our 3-year clinical experience in 200 patients with chronic plaque psoriasis.
Perlmutter A; Cather J; Franks B; Jaracz E; Menter A
J Am Acad Dermatol; 2008 Jan; 58(1):116-24. PubMed ID: 17997502
[TBL] [Abstract][Full Text] [Related]
15. An open-label study evaluating the efficacy and tolerability of alefacept for the treatment of scalp psoriasis.
Krell J; Nelson C; Spencer L; Miller S
J Am Acad Dermatol; 2008 Apr; 58(4):609-16. PubMed ID: 18262681
[TBL] [Abstract][Full Text] [Related]
16. Phase II clinical trial of bexarotene gel 1% in psoriasis.
Breneman D; Sheth P; Berger V; Naini V; Stevens V
J Drugs Dermatol; 2007 May; 6(5):501-6. PubMed ID: 17679184
[TBL] [Abstract][Full Text] [Related]
17. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis.
Lebwohl M; Christophers E; Langley R; Ortonne JP; Roberts J; Griffiths CE;
Arch Dermatol; 2003 Jun; 139(6):719-27. PubMed ID: 12810502
[TBL] [Abstract][Full Text] [Related]
18. The safety profile and sustained remission associated with response to multiple courses of intramuscular alefacept for treatment of chronic plaque psoriasis.
Roberts JL; Ortonne JP; Tan JK; Jaracz E; Frankel E;
J Am Acad Dermatol; 2010 Jun; 62(6):968-78. PubMed ID: 20392521
[TBL] [Abstract][Full Text] [Related]
19. Repeat courses of intravenous alefacept in patients with chronic plaque psoriasis provide consistent safety and efficacy.
Lowe NJ; Gonzalez J; Bagel J; Caro I; Ellis CN; Menter A
Int J Dermatol; 2003 Mar; 42(3):224-30. PubMed ID: 12653922
[TBL] [Abstract][Full Text] [Related]
20. Explorative immunohistochemical study to evaluate the addition of a topical corticosteroid in the early phase of alefacept treatment for psoriasis.
Bovenschen HJ; Gerritsen WJ; van Rens DW; Seyger MM; de Jong EM; van de Kerkhof PC
Arch Dermatol Res; 2007 Feb; 298(9):457-63. PubMed ID: 17136563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]